Search

Your search keyword '"Shah, Jay B."' showing total 212 results
Start Over Author "Shah, Jay B." Publication Type Academic Journals
212 results on '"Shah, Jay B."'

1. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Author

Einerhand, Sarah M. H., Black, Anna J., Zargar, Homayoun, Fairey, Adrian S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobson, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Kassouf, Wassim, Dall’Era, Marc A., Sridhar, Srikala S., McGrath, Jonathan S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Daneshmand, Siamak, Zargar-Shoshtari, Kamran, Spiess, Philippe E., van Rhijn, Bas W. G., Black, Peter C., and Mertens, Laura S.

Published
2022
Full Text
View/download PDF

2. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

Author

D’Andrea, David, Black, Peter C., Zargar, Homayoun, Zargar-Shoshtari, Kamran, Soria, Francesco, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, Dall’Era, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Shariat, Shahrokh F.

Published
2021
Full Text
View/download PDF

3. Risk of hospitalisation after primary treatment for prostate cancer

Author

Williams, Stephen B, Duan, Zhigang, Chamie, Karim, Hoffman, Karen E, Smith, Benjamin D, Hu, Jim C, Shah, Jay B, Davis, John W, and Giordano, Sharon H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Urologic Diseases, Prostate Cancer, Aging, Clinical Research, Aged, Brachytherapy, Hospitalization, Humans, Male, Odds Ratio, Propensity Score, Prostatectomy, Prostatic Neoplasms, Risk Factors, Survival Rate, Watchful Waiting, prostate cancer, treatments, hospitalisation, costs, utilisation, outcomes, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectiveTo compare the risk of hospitalisation and associated costs in patients after treatment for prostate cancer.Patients and methodsWe identified 29 571 patients aged 66-75 years without significant comorbidity from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database who were diagnosed with localised prostate cancer between 2004 and 2009. We compared the rates of all-cause and treatment-related hospitalisation that occurred within 365 days of the initiation of definitive therapy. We used multivariable logistic regression analysis to identify determinants associated with hospitalisation.ResultsMen who underwent radical prostatectomy (RP) rather than radiotherapy (RT) had lower odds of being hospitalised for any cause after therapy [odds ratio (OR) 0.80, 95% confidence interval (CI): 0.74-0.87]. Patients who underwent RP rather than RT had higher odds of being hospitalised for treatment-related complications (OR 1.15, 95% CI: 1.03-1.29). However, men who underwent external beam RT (EBRT)/intensity modulated RT (IMRT) (OR 0.84, 95% CI: 0.72-0.99) had a 16% lower odds of hospitalisation from treatment-related complications than patients undergoing RP. Using propensity score-weighted analyses there was no significant difference in the odds of hospitalisation from treatment-related complications for men who underwent RP vs RT (OR 1.06, 95% CI: 0.92-1.21). Patients hospitalised for treatment-related complications after RT were costlier than patients who underwent RP (Mean $18 381 vs $13 203, P < 0.001).ConclusionsWith the exception of men who underwent EBRT/IMRT, there was no statistically significant difference in the odds of hospitalisation from treatment-related complications. Costs from hospitalisation after treatment were significantly higher for men undergoing RT than RP. Our findings are relevant in the context of penalties linked to hospital readmissions and bundled payment models.

Published
2017

4. Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.

Author

Ladner, Tessa, Black, Anna J., Zargar, Homayoun, Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Cookson, Michael S., Jacobsen, Niels-Erik, Fairey, Adrian S., Dinney, Colin P. N., Mir, Maria C., Krabbe, Laura-Maria, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Stephenson, Andrew J., Shah, Jay B., and Daneshmand, Siamak

Published
2024
Full Text
View/download PDF

7. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

Author

Fransen van de Putte, Elisabeth E., Horenblas, Simon, Potvin, Kylea R., Winquist, Eric, Seah, Jo-An, Sridhar, Srikala S., Jacobsen, Niels-Erik, Zargar-Shoshtari, Kamran, Holzbeierlein, Jeff M., Griffin, Joshua, Dinney, Colin, Krabbe, Laura-Maria, Lotan, Yair, Kovac, Evan, Ercole, Cesar E., Stephenson, Andrew J., Grivas, Petros, Cookson, Michael S., Baras, Alex, Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Campain, Nicholas J., McGrath, John S., Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Dall'Era, Marc A., Barocas, Daniel A., Fairey, Adrian S., Shariat, Shahrokh F., Aning, Jonathan, Zargar, Homayoun, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Bivalacqua, Trinity J., Spiess, Philippe E., Black, Peter C., and Kassouf, Wassim

Published
2018
Full Text
View/download PDF

8. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study

Author

Bazargani, Soroush, Djaladat, Hoorman, Schuckman, Anne, Cookson, Michael, Cross, Brian, Stratton, Kelley, Lallas, Costas Dan, Gomella, Leonard, Mann, Mark, Johnson, Michael, Pierorazio, Phillip, McKiernan, James, Wenske, Sven, Sankin, Alexander, Merrill, Megan, Shabsigh, Ahmad, Nielsen, Matthew, Pruthi, Raj, Smith, Angela, Shah, Jay B., Taylor, Jennifer, Weight, Christopher, Daneshmand, Siamak, Patel, Sanjay, Lotan, Yair, Pohar, Kamal, Trabulsi, Edouard, Woods, Michael, Downs, Tracy, Huang, William, Jones, Jeffrey, O’Donnell, Michael, Bivalacqua, Trinity, DeCastro, Joel, Steinberg, Gary, Kamat, Ashish, Resnick, Matthew, Konety, Badrinath, Schoenberg, Mark, and Jones, J. Stephen

Published
2018
Full Text
View/download PDF

9. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

Author

Monteiro, Leonardo L., Witjes, J. Alfred, Agarwal, Piyush K., Anderson, Christopher B., Bivalacqua, Trinity J., Bochner, Bernard H., Boormans, Joost L., Chang, Sam S., Domínguez-Escrig, Jose L., McKiernan, James M., Dinney, Colin, Godoy, Guilherme, Kulkarni, Girish S., Mariappan, Paramananthan, O’Donnell, Michael A., Rentsch, Cyrill A., Shah, Jay B., Solsona, Eduardo, Svatek, Robert S., van der Heijden, Antoine G., van Valenberg, F. Johannes P., and Kassouf, Wassim

Published
2019
Full Text
View/download PDF

19. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Lotan, Yair, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., Black, Peter, Fairey, Adrian S., Mertens, Laura S., Horenblas, Simon, Dinney, Colin P., Mir, Maria C., Ercole, Cesar E., Stephenson, Andrew J., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Barocas, Daniel A., Griffin, Joshua, Holzbeierlein, Jeff M., Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Aning, Jonathan, Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Campain, Nicholas J., Pourmalek, Farshad, McGrath, John S., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Sridhar, Srikala S., Sharma, Pranav, Shariat, Shahrokh F., North, Scott, Grivas, Petros, Gandhi, Nilay, and Bivalacqua, Trinity J.

Published
2016
Full Text
View/download PDF

23. PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Gandhi, Nilay, Griffin, Joshua, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter C.

Published
2015
Full Text
View/download PDF

24. MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY

Author

Zargar-Shoshtari, Kamran, Zargar, Homayoun, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Gandhi, Nilay, Griffin, Joshua, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Sharma, Pranav, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter

Published
2015
Full Text
View/download PDF

30. PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN A MULTICENTRE COHORT OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER.: MP55-08

Author

Zargar, Homayoun, Fairey, Adrian S., Mertens, Laura, Espiritu, Patrick N., Dinney, Colin P., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Nils E., Montgomery, Jeffrey S., Gandhi, Nilay, Griffin, Joshua, Yu, Evan Y., Vasdev, Nikhil, Campain, Nicholas J., Xylinas, Evanguelos, Horenblas, Simon, Youssef, David, Kassouf, Wassim, Shariat, Shahrokh F., Aning, Jonathan J., Wright, Jonathan L., Thorpe, Andrew C., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., Morgan, Todd M., North, Scott, Barocas, Daniel A., Lotan, Yair, Shah, Jay B., Spiess, Philippe E., van Rhijn, B. W., Daneshmand, Siamak, and Black, Peter. C.

Published
2014
Full Text
View/download PDF

43. Innovative design/build approach: Ambassador Bridge project

Author

Shah, Jay B.

Subjects
Ambassador Bridge -- Maintenance and repair, Bridges -- Maintenance and repair, Business, Engineering and manufacturing industries
Abstract

The Ambassador Bridge, the busiest international crossing between the United States and Canada, is privately owned and operated, linking Detroit-Mich., with Windsor, Ontario. Since its inauguration in 1929, the bridge has not gone through any major upgrades or expansions. Due to many national and international developments (North American Free Trade Agreement) and significant increases in commercial traffic, the bridge required a major upgrade and expansion. The owners desired to complete the design and construction of a $3,000,000 truck-exit ramp within 12 months. The owners proposed a turnkey agreement that included several unique demands, such as 100 years of service life with 25 years of maintenance-free structure. Additionally, unique guarantees on costs and schedules, concealed conditions, and indemnifications were requested. The contract negotiated included many of the requested features that can be practically enforceable under the current professional practice, and construction liability laws and regulations. An independent business entity was utilized to address many of the owners' requirements, including hiring a construction company through a bidding process. The project was designed and built, according to state and federal standards, within the budget and the tight schedule of 12 months. The project was subsequently expanded under the same design/build contract to include an additional two phases at the cost of $8,500,000. The owners and consultants received many accolades and awards from civic and professional groups, including ASCE.

Published
1996

44. Performance appraisals for improved productivity

Author

Shah, Jay B. and Murphy, Joseph

Subjects
Performance appraisals -- Evaluation, Labor productivity -- Management, Business, Engineering and manufacturing industries
Abstract

Employee performance appraisal is a dynamic and evolving process for many civil engineering firms. As a tool to advance the interests of the civil engineering industry, a survey was conducted in 1981 to find out how various civil engineering firms manage their employee-appraisal programs. This paper summarizes the results of a follow-up survey recently conducted to track new trends in the performance-appraisal process. The findings of the survey were interesting in that many firms felt the employee-appraisal process helped enhance the performance of both the employee and the organization. The survey found that more firms today have formal employee-appraisal programs in place, and the majority of respondents believe appraisals help increase productivity and motivation if handled properly. The survey identified areas of the appraisal process that need to be improved: consistency in the process and timing; improved training; good follow-up; firm commitment from the top management; and more open, sincere discussions.

Published
1995

47. MP71-19 ULTRASENSITIVE URINARY LIQUID BIOPSY ANALYSIS FOR BCG RESPONSE ASSESSMENT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER.

Author

Shi, William Y., Liu, Kevin J., Esfahani, Mohammad S., Schroers-Martin, Joseph G., Nesselbush, Monica, Chen, Simon B., Alig, Stefan K., Mullane, Patrick, Mach, Kathleen E., Trabanino, Ludimila, Lee, Timothy J., Yoo, Ihna, La, Vinh, Rodriguez, Gabriela, Kornberg, Zachary, Shkolyar, Eugene, Gill, Harcharan, Thong, Alan, Shah, Jay B., and Prado, Kris

Subjects
NON-muscle invasive bladder cancer, BLADDER cancer, BCG immunotherapy, INTRAVESICAL administration, LIQUID analysis, TRANSURETHRAL resection of bladder
Published
2024
Full Text
View/download PDF

48. PD30-03 PREDICTING RESPONSE TO INTRAVESICAL BCG IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER USING AN ARTIFICIAL INTELLIGENCE-POWERED PATHOLOGY ASSAY: DEVELOPMENT AND VALIDATION IN AN INTERNATIONAL 12 CENTER COHORT.

Author

Lotan, Yair, Krishna, Viswesh, Launer, Bryn, Krishna, Vrishab, Singhi, Siddhant, Gordetsky, Jennifer, Shah, Jay B., Gerald, Thomas, Shkolyar, Eugene, Hayne, Dickon, Redfern, Andrew, Spalding, Lisa, Stewart, Courtney, Narayan, Vikram, Patil, Dattatraya, Packiam, Vignesh T., Rajan, Anand, O'Donnell, Michael A., Baekelandt, Loic, and Fernandez, Mario I.

Subjects
BLADDER cancer, NON-muscle invasive bladder cancer, BCG immunotherapy, TRANSURETHRAL resection of bladder
Published
2024
Full Text
View/download PDF

49. PD27-12 DEVELOPMENT AND VALIDATION OF GENERALIZABLE INTERPRETABLE AI BIOMARKERS TO PREDICT CLINICAL OUTCOMES IN BCG-TREATED PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER.

Author

Lotan, Yair, Shah, Jay B., Krishna, Viswesh, Launer, Bryn, Krishna, Vrishab, Shingi, Siddhant, Gordetsky, Jennifer, Gerald, Thomas, Shkolyar, Eugene, Hayne, Dickon, Redfern, Andrew, Spalding, Lisa, Stewart, Courtney, Narayanan, Vikram, Patil, Dattatreya, Packiam, Vignesh T., Rajan, Anand, O'Donnell, Michael A., Baekelandt, Loic, and Fernandez, Mario I.

Subjects
BLADDER cancer, NON-muscle invasive bladder cancer, TREATMENT effectiveness, ARTIFICIAL intelligence
Published
2024
Full Text
View/download PDF

50. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.

Author

Mmeje, Chinedu O., Benson, Cooper R., Nogueras‐González, Graciela M., Jayaratna, Isuru S., Gao, Jianjun, Siefker‐Radtke, Arlene O., Kamat, Ashish M., Dinney, Colin P., Navai, Neema, and Shah, Jay B.

Subjects
CYSTECTOMY, BLADDER cancer, LYMPH nodes, CANCER chemotherapy, ONCOLOGIC surgery
Abstract

Objective: To determine whether the recovery window (RW) between neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) affects 90‐day postoperative morbidity and incidence of lymph node metastasis. Patients and methods: We reviewed patients treated with NAC and RC from 1995 to 2013 for ≤cT4N0M0 bladder cancer. The association of the RW with 90‐day perioperative morbidity and lymph node metastasis was determined. Generalised linear models were used to determine predictors of each endpoint. Patients were stratified into four RWs by 21‐day intervals (18–42; 43–63; 64–84; and ≥85 days) from last day of NAC to RC. Results: We evaluated 306 patients with RW information during the study period. The median (range) RW was 46 (18–199) days. There was no difference in overall morbidity, re‐admission, or major complication rates amongst the four RWs. In the multivariable analysis extravesical disease was an independent predictor of overall morbidity (odds ratio [OR] 1.95, 95% confidence interval [CI] 1.16–3.26; P = 0.011). Age (OR 1.05, 95% CI: 1.02–1.09; P = 0.004), and surgical duration ≥7 h (OR 2.87, 95% CI: 1.52–5.42; P = 0.001) were independent predictors of major complications. Only surgical duration ≥7 h was a predictor of re‐admission (OR 2.24; 95% CI: 1.26–3.98; P = 0.006). A RW of ≥85 days had the highest incidence of node‐positive disease (pN+; 40%). In a separate multivariable model that included clinical predictors for pN+, a RW of ≥85 days was an independent predictor of nodal metastasis (OR 2.92, 95% CI: 1.20–7.09; P = 0.018). Conclusion: Patients treated with NAC for bladder cancer can undergo RC between 18 and 84 days (2.5–12 weeks) after NAC with no difference in the risk of perioperative morbidity. Delaying surgery beyond 12 weeks was associated with a significant risk of lymph node metastasis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results